OLD Category: Oncology

Consensus Molecular Subtypes (CMS) in Metastatic Colorectal Cancer – Personalized Medicine Decision

• Rebersek M

Prognostic gene expression signature for high-grade serous ovarian cancer

• Millstein J, Budden T, Goode EL, Doherty JA, Pharoah PDP, Ramus SJ

Deep immune profiling of patients treated with lenalidomide and dexamethasone with or without daratumumab

• Casneuf T, Adams HC, van de Donk NW...Schecter JM, Chiu C, Bahlis NJ

The Possible Influence of Mediterranean Diet on Extracellular Vesicle miRNA Expression in Breast Cancer Survivors

• Kwon YJ, Cho YE, Cho AR...Gill J, Lee H, Lee JW

Digital spatial profiling application in breast cancer: a user’s perspective

• McCart Reed AE, Bennett J, Kutasovic JR, Yeong J, Simpson PT, Lakhani SR

Cytotoxic T-cell-related gene expression signature predicts improved survival in muscle-invasive urothelial bladder cancer patients after radical cystectomy and adjuvant chemotherapy

• Eckstein M, Strissel P, Strick R, Weyerer V, Wirtz R, Pfannstiel C, Wullweber A, Lange F, Erben P, Stoehr R, Bertz S, Geppert CI, Fuhrich N, Taubert H, Wach S, Breyer J, Otto W, Burger M, Bolenz C, Keck B, Wullich B, Hartmann A, Sikic D; BRIDGE Consortium e.V., Mannheim, Germany.

High-Content Phenotypic Profiling in Esophageal Adenocarcinoma Identifies Selectively Active Pharmacological Classes of Drugs for Repurposing and Chemical Starting Points for Novel Drug Discovery

• Hughes RE, Elliott RJR, Munro AF, Makda A, O’Neill JR, Hupp T, Carragher NO

Combining gene expression profiling and machine learning to diagnose B-cell non-Hodgkin lymphoma

• Bobée V, Drieux F, Marchand V, Sater V, Veresezan L, Picquenot JM, Viailly PJ, Lanic MD, Viennot M, Bohers E, Oberic L, Copie-Bergman C, Molina TJ, Gaulard P, Haioun C, Salles G, Tilly H, Jardin F, Ruminy P.

Tumor Cell Associated Hyaluronan-CD44 Signaling Promotes Pro-Tumor Inflammation in Breast Cancer

• Witschen PM, Chaffee TS, Brady NJ, Huggins DN, Knutson TP, LaRue RS, Munro SA, Tiegs L, McCarthy JB, Nelson AC, Schwertfeger KL.

Ibrutinib Resistance Mechanisms and Treatment Strategies for B-Cell Lymphomas

• George B, Mullick Chowdhury S, Hart A, Sircar A, Singh SK, Nath UK, Mamgain M, Singhal NK, Sehgal L, Jain N

Effects of B cell–activating factor on tumor immunity

• Yarchoan M, Ho WJ, Mohan A, Shah Y, Vithayathil T, Leatherman J, Dennison L, Zaidi N, Ganguly S, Woolman S, Cruz K, Armstrong TD, Jaffee EM.

PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations

• Fabian KP, Padget MR, Donahue RN, Solocinski K, Robbins Y, Allen CT, Lee JH, Rabizadeh S, Soon-Shiong P, Schlom J, Hodge JW.